SeaStar Medical Holding Corp (NASDAQ: ICU)

SeaStar Medical Holding Corp, known by its stock symbol ICU, is a clinical-stage medical technology company operating within the healthcare industry. The company's primary business activities revolve around the development of its Selective Cytopheretic Device (SCD), an extracorporeal synthetic membrane device designed to bind activated neutrophils and monocytes as part of a CRRT (continuous renal replacement therapy) extracorporeal circuit. This innovative technology aims to attenuate the excessive inflammatory response of activated neutrophils and monocytes, thereby reducing tissue damage and accelerating the repair and recovery of organ function in patients suffering from hyperinflammation.

The company's primary product is its SCD device, which is designed to treat acute kidney injury (AKI) in both pediatric and adult patients undergoing CRRT. The SCD device is easily integrated into existing CRRT systems commonly found in hospitals, including ICUs across the United States. SeaStar Medical's customer base primarily consists of hospitals and clinicians treating patients with AKI, a condition that often necessitates CRRT.

SeaStar Medical's position within the industry is unique due to its SCD technology, which has the potential to transform the treatment of AKI and other inflammatory disorders. The SCD technology has demonstrated the ability to selectively bind and deactivate the most highly activated neutrophils and monocytes, allowing the body to restore neutrophil homeostasis. This groundbreaking approach has earned the company Breakthrough Device Designations from the FDA for its SCD device in three indications: AKI in adult patients, cardiorenal syndrome, and acute on chronic liver failure. These designations are expected to expedite the clinical development and regulatory review of the SCD device for use in these indications.

The company's clinical-stage product candidates include Quelimmune, which is being evaluated in a pivotal study for adult AKI patients. Additionally, SeaStar Medical has submitted an HDE application to the FDA for its SCD device for the treatment of pediatric patients with AKI undergoing CRRT. The company's growth strategies encompass innovating and expanding its applications through clinical trials, differentiating itself through medical education, engaging in business development and out-licensing activities, and scaling production with manufacturing partners. SeaStar Medical believes its SCD technology has the potential to apply to multiple indications and is actively exploring business development opportunities with major medical and pharmaceutical companies to establish partnerships and out-license its technology.

In addition to its SCD technology, SeaStar Medical is evaluating the safety and efficacy of its SCD in other patient populations, such as those with cardiorenal syndrome, hepatorenal syndrome, and myocardial ischemia in end-stage renal disease patients on chronic hemodialysis. The company has secured a supplier for the filter used in its pediatric AKI indication and is developing a second source for adult and pediatric filters. Furthermore, SeaStar Medical has entered into a supply agreement with Fresenius Medical Care North America to supply certain filters at an agreed amount per case for use in its SCD product in its upcoming clinical trial and any additional clinical trials.

SeaStar Medical's distribution strategy involves appointing Nuwellis as its exclusive distributor for the sale and distribution of the SCD product throughout the United States once it receives written authorization from the FDA to market its SCD for pediatric use. The company's reimbursement strategy includes achieving alignment and agreement from CMS on coding and payment pathways, both of which are crucial for optimal reimbursement payment from private payor sources. SeaStar Medical is pursuing a regulatory reimbursement strategy to ensure separate Medicare payment for its SCD at an appropriate price.